Great Point Partners 13F annual report
Great Point Partners is an investment fund managing more than $522 billion ran by Dr. M.d.. There are currently 33 companies in M.d.’s portfolio. The largest investments include UroGen Pharma Ltd and Neurogene Inc, together worth $85.3 billion.
$522 billion Assets Under Management (AUM)
As of 7th August 2024, Great Point Partners’s top holding is 2,906,259 shares of UroGen Pharma Ltd currently worth over $48.8 billion and making up 9.3% of the portfolio value.
Relative to the number of outstanding shares of UroGen Pharma Ltd, Great Point Partners owns less than approximately 0.1% of the company.
In addition, the fund holds 1,004,291 shares of Neurogene Inc worth $36.5 billion.
The third-largest holding is Abivax Sa worth $32.7 billion and the next is Merus N.V worth $31 billion, with 523,288 shares owned.
Currently, Great Point Partners's portfolio is worth at least $522 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Great Point Partners
The Great Point Partners office and employees reside in Greenwich, Connecticut. According to the last 13-F report filed with the SEC, Dr. M.d. serves as the Senior Managing Member at Great Point Partners.
Recent trades
In the most recent 13F filing, Great Point Partners revealed that it had opened a new position in
Neurogene Inc and bought 1,004,291 shares worth $36.5 billion.
The investment fund also strengthened its position in UroGen Pharma Ltd by buying
2,346,259 additional shares.
This makes their stake in UroGen Pharma Ltd total 2,906,259 shares worth $48.8 billion.
UroGen Pharma Ltd dropped 33.9% in the past year.
On the other hand, there are companies that Great Point Partners is getting rid of from its portfolio.
Great Point Partners closed its position in Vaxcyte on 14th August 2024.
It sold the previously owned 800,000 shares for $38.4 billion.
One of the average hedge funds
The two most similar investment funds to Great Point Partners are Walter Public Investments and Ratio Wealth. They manage $523 billion and $523 billion respectively.
Dr. M.d. investment strategy
Great Point Partners’s portfolio is diversified across 3 sectors.
Currently, their heaviest sector is Health Care — making up 61.5% of
the total portfolio value.
The fund focuses on investments in the United States as
54.5% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
9% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $1.02 billion.
The complete list of Great Point Partners trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| UroGen Pharma Ltd |
418.97%
2,906,259
|
$48,767,026,000 | 9.34% |
| Vaxcyte, Inc. |
Closed
800,000
|
$38,360,000,000 | |
| Neurogene Inc |
Opened
1,004,291
|
$36,546,149,000 | 7.00% |
| Xenon Pharmaceuticals Inc |
Closed
850,000
|
$33,515,500,000 | |
| Abivax Sa |
Opened
2,472,188
|
$32,682,325,000 | 6.26% |
| Merus N.V |
Opened
523,288
|
$30,962,951,000 | 5.93% |
| RAPT Therapeutics, Inc. |
Closed
1,436,569
|
$28,444,066,000 | |
| Pliant Therapeutics, Inc. |
99.33%
2,636,864
|
$28,346,288,000 | 5.43% |
| Arcellx Inc |
Opened
492,000
|
$27,153,480,000 | 5.20% |
| Alpine Immune Sciences Inc |
Closed
3,637,718
|
$26,737,227,000 | |
| Dynavax Technologies Corp. |
Opened
2,374,000
|
$26,660,020,000 | 5.11% |
| Evolus Inc |
1,188.18%
2,451,772
|
$26,601,726,000 | 5.10% |
| Cytokinetics Inc |
Opened
474,202
|
$25,692,264,000 | 4.92% |
| Jazz Pharmaceuticals plc |
Closed
160,000
|
$25,489,600,000 | |
| Seagen Inc |
Closed
160,500
|
$20,625,855,000 | |
| Dianthus Therapeutics Inc |
Opened
757,929
|
$19,615,203,000 | 3.76% |
| Point Biopharma Global Inc |
Closed
2,541,779
|
$18,529,569,000 | |
| IVERIC bio Inc |
Closed
825,000
|
$17,663,250,000 | |
| Insmed Inc |
Opened
250,000
|
$16,750,000,000 | 3.21% |
| Zura Bio Ltd |
Opened
4,642,241
|
$16,247,844,000 | 3.11% |
| Aclaris Therapeutics Inc |
Closed
1,019,282
|
$16,053,692,000 | |
| Heron Therapeutics Inc |
Closed
6,360,161
|
$15,900,403,000 | |
| Ultragenyx Pharmaceutical In |
Closed
342,300
|
$15,858,759,000 | |
| KalVista Pharmaceuticals Inc |
26.78%
1,338,568
|
$15,768,331,000 | 3.02% |
| Ionis Pharmaceuticals Inc |
Opened
330,000
|
$15,727,800,000 | 3.01% |
| Context Therapeutics Inc |
Opened
7,419,355
|
$14,875,807,000 | 2.85% |
| Amicus Therapeutics Inc |
Opened
1,495,500
|
$14,835,360,000 | 2.84% |
| OptiNose Inc |
73.88%
13,727,097
|
$14,276,181,000 | 2.73% |
| Ventyx Biosciences Inc |
Closed
400,695
|
$13,138,789,000 | |
| Esperion Therapeutics Inc Ne |
Opened
5,791,594
|
$12,857,339,000 | 2.46% |
| Voyager Therapeutics Inc |
Opened
1,601,527
|
$12,668,079,000 | 2.43% |
| Outlook Therapeutics Inc |
Opened
1,701,510
|
$12,557,144,000 | 2.41% |
| Cincor Pharma Inc |
Closed
1,019,153
|
$12,525,390,000 | |
| Viking Therapeutics Inc |
Closed
1,295,034
|
$12,173,320,000 | |
| Autolus Therapeutics plc |
Opened
3,441,667
|
$11,977,001,000 | 2.29% |
| Day One Biopharmaceuticals I |
Closed
544,451
|
$11,716,586,000 | |
| PTC Therapeutics Inc |
Closed
302,135
|
$11,532,493,000 | |
| Aerovate Therapeutics Inc |
Closed
378,522
|
$11,090,695,000 | |
| Travere Therapeutics Inc |
Closed
475,000
|
$9,989,250,000 | |
| Cymabay Therapeutics Inc |
Closed
1,550,000
|
$9,718,500,000 | |
| Sarepta Therapeutics Inc |
Closed
73,000
|
$9,459,340,000 | |
| Jasper Therapeutics Inc |
Opened
402,015
|
$9,125,741,000 | 1.75% |
| Olema Pharmaceuticals, Inc. |
Opened
796,880
|
$8,622,242,000 | 1.65% |
| Terns Pharmaceuticals Inc |
Opened
1,149,406
|
$7,827,455,000 | 1.50% |
| Amylyx Pharmaceuticals Inc |
Closed
190,000
|
$7,020,500,000 | |
| Moonlake Immunotherapeutics |
Closed
642,566
|
$6,746,943,000 | |
| Erasca Inc |
Closed
1,538,461
|
$6,630,767,000 | |
| Intercept Pharmaceuticals In |
Closed
528,850
|
$6,541,875,000 | |
| Viridian Therapeutics Inc |
Opened
500,000
|
$6,505,000,000 | 1.25% |
| Acumen Pharmaceuticals Inc |
Closed
1,116,581
|
$6,029,537,000 | |
| Mirati Therapeutics Inc |
Closed
133,000
|
$6,026,230,000 | |
| Verve Therapeutics Inc |
Closed
300,000
|
$5,805,000,000 | |
| Albireo Pharma Inc |
Closed
267,283
|
$5,775,986,000 | |
| Tscan Therapeutics Inc |
Opened
940,831
|
$5,503,861,000 | 1.05% |
| Vistagen Therapeutics Inc. |
Opened
1,529,338
|
$5,322,096,000 | 1.02% |
| Larimar Therapeutics, Inc. |
Closed
1,273,635
|
$5,260,113,000 | |
| Helix Acquisition Corp Ii |
Opened
500,000
|
$5,110,000,000 | 0.98% |
| Puma Biotechnology Inc |
Opened
1,486,544
|
$4,846,133,000 | 0.93% |
| Precision BioSciences, Inc. |
Closed
3,801,305
|
$4,523,553,000 | |
| Gracell Biotechnologies Inc. |
Closed
1,962,399
|
$4,513,518,000 | |
| Generation Bio Co. |
Closed
1,022,537
|
$4,018,570,000 | |
| Kyverna Therapeutics Inc |
Opened
499,152
|
$3,743,640,000 | 0.72% |
| Spyre Therapeutics Inc |
Opened
134,612
|
$3,164,728,000 | 0.61% |
| Alkermes plc |
Closed
46,185
|
$1,206,814,000 | |
| Immunic, Inc. |
Closed
632,184
|
$885,058,000 | |
| AnaptysBio Inc |
66.67%
25,000
|
$626,500,000 | 0.12% |
| Lexicon Pharmaceuticals Inc |
Opened
30,000
|
$50,400,000 | 0.01% |
| No transactions found | |||
| Showing first 500 out of 67 holdings | |||
Hedge funds similar to Great Point Partners
- Tennessee Valley Asset Management Partners
- Alpha Omega Wealth Management
- Portside Wealth
- Hoey Investments, Inc
- Baron Silver Stevens Financial Advisors
- Ratio Wealth
- Walter Public Investments
- Peninsula Wealth
- Allen Mooney & Barnes Investment Advisors
- Private Asset Management Inc
- Squadra Investments - Gestao De Recursos Ltda
- Pacific Capital Wealth Advisors, Inc
- Duncker Streett & Co Inc
- Cutter Capital Management, L.P.